High Molecular Weight Kininogen Deficiency: a Patient who Underwent Cardiac Surgery

S. J. Davidson; J. F. Burman; L. C. Rutherford; B. F. Keogh; M. H. Yacoub

doi:10.1055/s-0037-1615675

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2001; 85(02): 195-197
DOI: 10.1055/s-0037-1615675

Rapid Communications

Schattauer GmbH

High Molecular Weight Kininogen Deficiency: a Patient who Underwent Cardiac Surgery

Authors

S. J. Davidson

¹Departments of Haematology, Royal Brompton Hospital, London, UK
J. F. Burman

¹Departments of Haematology, Royal Brompton Hospital, London, UK
L. C. Rutherford

¹Departments of Haematology, Royal Brompton Hospital, London, UK
B. F. Keogh

²Departments of Anaesthesia, Royal Brompton Hospital, London, UK
M. H. Yacoub

³Departments of Academic Surgery, Royal Brompton Hospital, London, UK

Abstract

Summary

A 66 year old male, referred for cardiac surgery, was found to have high molecular weight kininogen deficiency (activity <1%). Apart from activated partial thromboplastin time (APTT) >300 s, tests of haemostasis were otherwise normal (factors VIII, IX, XI, XII and prekallikrein). No inhibitor of coagulation was found.

The activated coagulation time (ACT) was 800 s pre-operatively and >1000 s after heparin. Heparin levels were measured directly by an anti-Xa chromogenic assay, with values of between 2.9 and 3.2 u/ml during cardiopulmonary bypass. Thrombin-antithrombin levels rose from 2.3*g/l before surgery to a peak of 83.5*g/l at the end of cardio-pulmonary bypass. Cross linked fibrin d-dimers (XDP) levels rose from 100 ng/ml before operation to 600 ng/ml after protamine administration. The patient had no excess bleeding and no thrombotic complications from surgery.

This patient shows that high molecular weight kininogen is not required for thrombin formation or fibrinolysis during cardiac surgery and illustrates the need to measure heparin directly in patients with such contact factor deficiencies.

Keywords

High molecular weight kininogen - cardiopulmonary bypass - thrombin - fibrinolysis

Full Text

References

References
1 Colman RW, Schmaier AH. Contact system: A vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive and proinflammatory attributes. Blood 1997; 90: 3819-43.
2 Bradford HN, DeLa Cadena RA, Kunapuli SP, Dong J-F, López JA, Colman RW. Human kininogens regulate thrombin binding to platelets through the glycoprotein Ib-IX-V complex. Blood 1997; 90: 1508-15.
3 Hasan AA, Cines DB, Ngaiza JR, Jaffe EA, Schmaier AH. High-molecular-weight kininogen is exclusively membrane bound on endothelial cells to influence activation of the vascular endothelium. Blood 1995; 85: 3134-43.
4 Colman RW, Bagdasarian A, Talamo RC, Scott CF, Seavey M, Guimaraes JA, Pierce JV, Kaplan AP. Williams trait. Human kininogen deficiency with diminished levels of plasminogen proactivator and prekallikrein associated with abnormalities of the Hageman factor-dependent pathways. J Clin Invest 1975; 56: 1650-62.
5 Wuepper KD, Miller DR, Lacombe MJ. Flaujeac trait. Deficiency of human plasma kininogen. J Clin Invest 1975; 56: 1663-72.
6 Lefrère J-J, Horellou M-H, Gozin D, Conard J, Muller J-Y, Clark M, Soulier J-P, Samama M. A new case of high-molecular-weight kininogen inherited deficiency. Am J Hematol 1986; 22: 415-9.
7 Hayashi H, Ishimaru F, Fujita T, Tsurumi N, Tsuda T, Kimura I. Molecular genetic survey of five Japanese families with high-molecular-weight kininogen deficiency. Blood 1990; 75: 1296-304.
8 Exner T, Barber S, Naujalis J. Fitzgerald factor deficiency in an Australian aborigine. Med J. Aust 1987; 146: 545-7.
9 Hayashi H, Koya H, Kuroda M, Kitazima K, Kimura I, Katori M, Oh-ishi S. The first cases of Fitzgerald factor deficiency in the Orient: three cases in one family. Acta Haematol 1980; 63: 107-13.
10 Hutt ED, Kingdon HS. Use of heparinase to eliminate heparin inhibition in routine coagulation assays. J Lab Clin Med 1972; 79: 1027-34.
11 Burman JF, Chung HI, Lane DA, Philippou H, Adami A, Lincoln JCR. Role of factor XII in thrombin generation and fibrinolysis during cardio-pulmonary bypass. Lancet 1994; 344: 1192-3.
12 Candio J, Prager D. Cardiopulmonary bypass and factor XII deficiency. Pa Med 1981; 84 no 2 40.
13 Kelsey PR, Bottomley J, Grotte GJ, Maciver JE. Congenital factor XII deficiency: successful open heart surgery and anticoagulation. Clin Lab Haematol 1985; 7: 379-81.
14 Salmenperä M, Rasi V, Mattila S. Cardiopulmonary bypass in a patient with factor XII deficiency. Anesthesiology 1991; 75: 539-41.
15 Wood MK. Congenital factor XII deficiency and cardiopulmonary bypass. Ann Thorac Surg 1994; 58: 1565.
16 Moorman RM, Reynolds DS, Comunale ME. Management of cardiopulmonary bypass in a patient with congenital factor XII deficiency. J Cardiothorac Vasc Anesth 1993; 7: 452-4.
17 Boisclair MD, Lane DA, Philippou H, Sheikh S, Hunt B. Thrombin production, inactivation and expression during open heart surgery measured by assays for activation fragments including a new ELISA for prothrombin fragment F1+2. Thromb Haemost 1993; 70: 253-8.
18 Boisclair MD, Lane DA, Philippou H, Esnouf MP, Sheikh S, Hunt B, Smith KJ. Mechanisms of thrombin generation during surgery and cardio-pulmonary bypass. Blood 1993; 82: 3350-7.
19 Chung JH, Gikakis N, Rao AK, Drake TA, Colman RW, Edmunds LH. Pericardial blood activates the extrinsic coagulation pathway during clinical cardiopulmonary bypass. Circulation 1996; 93: 2014-8.
20 Chung HI, Burman JF, Balogun BA, Lincoln JCR, Pepper JR. Elevated fibrinolysis in cardiopulmonary bypass is factor XII dependent. Fibrinolysis 1994; 8 (Suppl. 02) 84-5.
21 Hattersley PG. Activated coagulation time of whole blood. J Am Med Assoc 1966; 196: 436-40.